1-20 of 2,775 results for member:"Lord Goodlad"
Librarians' tools
- Search time
- 0.879 seconds
- Solr query time
- 0.008 seconds
- Search query
- member:"Lord Goodlad"
- We searched for
- member_ses:300835
Type
House
Session
Year
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
My Lords, it is a great pleasure to follow the noble Baroness, Lady Liddell, who made such a distinguished contribution to British-Australian relations when she was high commissioner—comprehensively erasing my footprints in the process, not least in bilateral trade and investment promotion, which is an important part of the job....
My Lords, it is a great pleasure to follow the noble Baroness, Lady Liddell, who made such a distinguished contribution to British-Australian relations when she was high commissioner—comprehensively erasing my footprints in the process, not least in bilateral trade and investment promotion, which is an important part of the job....
To ask His Majesty's Government how the 10 year plan for dementia will prepare the NHS for the arrival of new dementia treatments, such as Lecanemab.
To ask His Majesty's Government how the 10 year plan for dementia will prepare the NHS for the arrival of new dementia treatments, such as Lecanemab.
We are reviewing plans for dementia in England and further information will be available in due course. NHS England continuously reviews potentially promising new medicines which might provide benefits to patients in future, including Lecanemab.
To ask His Majesty's Government what discussions they have had about improving dementia diagnosis to prepare for the arrival of Lecanemab.
To ask His Majesty's Government what discussions they have had about improving dementia diagnosis to prepare for the arrival of Lecanemab.
We have had no specific discussions. NHS England continuously reviews potentially promising new medicines which might provide benefits to patients in future, including Lecanemab.
To ask His Majesty's Government what discussions the Home Office has had with the Association of Directors of Public Health in the last six months about notifiable diseases at the Western Jet Foil and Manston Processing Centres; and what was the outcome of any such discussions.
To ask His Majesty's Government what discussions the Home Office has had with the Association of Directors of Public Health in the last six months about notifiable diseases at the Western Jet Foil and Manston Processing Centres; and what was the outcome of any such discussions.
The Home Office has regular engagement with the UK Health Security Agency (UKHSA) on matters of communicable and notifiable diseases detected at Western Jetfoil and Manston.
Directors of Public Health do attend operational asylum accommodation meetings relating specifically to health, either in person or through representatives. These are multi-agency forums, where any issues or concerns around the management of infectious diseases in asylum accommodation can be discussed. However, the collaborative approach to managing communicable diseases within the context of Manston and Western Jetfoil and reducing the risk of their spreading is led by UKHSA and supported by the Home Office.
The Home Office and DLUHC 2nd Permanent Secretary wrote to Directors of Public Health, outlining the Home Office's ongoing programme of work to limit the spread of infectious diseases in hotels.
To ask His Majesty's Government, further to the Written Answer by Lord Murray of Blidworth on 16 November (HL3143), (1) how many, and (2) which, cases of notifiable diseases in the Western Jet Foil and Manston Asylum Processing Centre have been referred to the UK Health Security Agency.
To ask His Majesty's Government, further to the Written Answer by Lord Murray of Blidworth on 16 November (HL3143), (1) how many, and (2) which, cases of notifiable diseases in the Western Jet Foil and Manston Asylum Processing Centre have been referred to the UK Health Security Agency.
The Home Office works closely with UKHSA and the NHS in tracking those with communicable diseases.
Any cases of Communicable diseases are dealt with in conjunction with UKHSA local Health Protection Team and this includes creating a pathway for the safe dispersals of persons with communicable diseases from site into appropriate accommodation ensuring all relevant parties are informed prior to the dispersal. Any decisions are taken in liaison with UKHSA and local NHS partners.
To ask His Majesty's Government whether any notifiable diseases, as defined by the Public Health Control of Diseases Act 1984, have been identified as present in the Western Jet Foil and Manston Asylum Processing Centre; and if so, what steps they are taking as a result.
To ask His Majesty's Government whether any notifiable diseases, as defined by the Public Health Control of Diseases Act 1984, have been identified as present in the Western Jet Foil and Manston Asylum Processing Centre; and if so, what steps they are taking as a result.
All suspected cases of communicable disease are isolated in line with public health guidance. Every confirmed case is referred to the UK Health Security Agency by the laboratory.
To ask His Majesty's Government what representations they have made to the government of France about the implementation of the 1995 agreement on the return of illegal immigrants; and what was the outcome of these discussions.
To ask His Majesty's Government what representations they have made to the government of France about the implementation of the 1995 agreement on the return of illegal immigrants; and what was the outcome of these discussions.
The 1995 agreement continues to be used to manage migration flows between France and the UK. It enables the return of illegal migrants seeking to irregularly enter both the UK and France.
The agreement is invoked when an individual without leave in either the UK or France seeks to enter via the Eurotunnel or Channel Port, when we can clearly indicate the time of embarkation and the individual does not claim asylum at the port.
We continue to work with France on this global migration crisis. We are aiming for solutions to collectively address the wide range of factors associated with migrant movements across Europe and the Channel.
My Lords, I congratulate my noble friend Lady Anelay and the committee on the report and my noble friend on her speech introducing the debate today. Much has taken place since the publication of the report, all of which underlines the importance of its deliberations and recommendations.
It is a great...
My Lords, I congratulate my noble friend Lady Anelay and the committee on the report and my noble friend on her speech introducing the debate today. Much has taken place since the publication of the report, all of which underlines the importance of its deliberations and recommendations.
It is a great...
My Lords, I congratulate the noble Lord, Lord Hunt of Kings Heath, on initiating this timely debate and thank the noble Baroness, Lady Wheeler, for stepping in and speaking so knowledgeably and authoritatively. As she said, this country is a world leader in the life sciences, and we now face...
My Lords, I congratulate the noble Lord, Lord Hunt of Kings Heath, on initiating this timely debate and thank the noble Baroness, Lady Wheeler, for stepping in and speaking so knowledgeably and authoritatively. As she said, this country is a world leader in the life sciences, and we now face...
To ask Her Majesty's Government when they will publish the terms of reference for the National Dementia Mission.
To ask Her Majesty's Government when they will publish the terms of reference for the National Dementia Mission.
Since its launch, we have commenced the recruitment process for the Chair of the Mission. Once the Chair has been appointed, governance structures and terms of reference will be developed.
To ask Her Majesty's Government when they will set out their spending plan to meet the target to increase dementia research funding to £160 million per year by 2024.
To ask Her Majesty's Government when they will set out their spending plan to meet the target to increase dementia research funding to £160 million per year by 2024.
There is no intention to set out a specific spending plan.
To ask Her Majesty's Government how civil servants will support the delivery of the National Dementia Mission.
To ask Her Majesty's Government how civil servants will support the delivery of the National Dementia Mission.
Civil servants from the Office for Life Sciences, Department for Health and Social Care and Department for Business, Energy and Industrial Strategy have been developing the Mission and will continue to be represented in any new governance structures and in supporting the Chair, once recruited. The Senior Responsible Officer for the mission will also be a civil servant.
My Lords, I too congratulate my noble friend Lord Howell on securing this debate and on his wise, perceptive remarks. He has personally made a distinguished contribution to the Commonwealth in various capacities. I also pay tribute to my noble friend Lord Marland’s work for the Commonwealth Business Council, whose...
My Lords, I too congratulate my noble friend Lord Howell on securing this debate and on his wise, perceptive remarks. He has personally made a distinguished contribution to the Commonwealth in various capacities. I also pay tribute to my noble friend Lord Marland’s work for the Commonwealth Business Council, whose...
To ask Her Majesty's Government what steps they are taking to mitigate the effects of bird flu in Shetland.
To ask Her Majesty's Government what steps they are taking to mitigate the effects of bird flu in Shetland.
Disease control is a devolved matter, and it is for the devolved administrations to assess their disease risks and respond accordingly. However, each of the administrations seeks consistent and coordinated response to disease control across Great Britain (GB) where possible. Avian influenza control measures for the three GB administrations are set out in the GB notifiable avian disease control strategy (copy also attached to this answer).
As part of the coordinated GB response to avian influenza, the Animal and Plant Health Agency (APHA) carries out year-round avian influenza surveillance of dead wild birds submitted via public reports and warden patrols on behalf of Defra, the Scottish Government and the Welsh Government to help us understand how the disease is distributed geographically and in different types of bird. Through this surveillance, wild birds including Eider ducks, great black-backed gulls, gannets and Arctic terns have been found positive for highly pathogenic avian influenza (HPAI) H5N1 on Shetland. The Scottish Government is working closely with APHA, NatureScot and other non-governmental organisations including the Royal Society for the Protection of Birds and the British Trust for Ornithology to monitor and respond to the effect of avian influenza on wild birds on Shetland and other areas of Scotland.
My Lords, I welcome the Government’s commitment in the gracious Speech to bring forward a draft mental health Bill. I hope that the consultation, ending in June, will be followed by early legislation. I particularly hope that the provisions of the Bill will address dementia, which is the fastest-growing health...
My Lords, I welcome the Government’s commitment in the gracious Speech to bring forward a draft mental health Bill. I hope that the consultation, ending in June, will be followed by early legislation. I particularly hope that the provisions of the Bill will address dementia, which is the fastest-growing health...
To ask Her Majesty's Government what discussions they have had regarding the provision of (1) hearing aids, (2) stop smoking services, and (3) treatment for hypertension, to (a) reduce dementia risk, and (b) promote brain health.
To ask Her Majesty's Government what discussions they have had regarding the provision of (1) hearing aids, (2) stop smoking services, and (3) treatment for hypertension, to (a) reduce dementia risk, and (b) promote brain health.
There have been no specific discussions. However, the Department is preparing a new dementia strategy, which will include a focus on prevention and risk reduction. As part of this work, in December 2021 the Department had discussions with the British Academy of Audiology on hearing loss as a risk factor for dementia.
To ask Her Majesty's Government what plans they have to improve the (1) approval, and (2) set-up processes, for dementia trials.
To ask Her Majesty's Government what plans they have to improve the (1) approval, and (2) set-up processes, for dementia trials.
The Future of UK Clinical Research Delivery: 2021 to 2022 Implementation Plan sets out our commitments to improve study approval and set-up processes. This states that the Medicines and Healthcare products Regulatory Agency and the UK Research Ethics Services plan to implement a combined review of clinical trials to improve study approval. It aims to deliver a streamlined and efficient approval process through a single application route and a coordinated review. We also plan to introduce a National Contract Value Review to accelerate commercial research studies in the National Health Service. While the Implementation Plan is not specific to any disease area, it aims to benefit the research system, including trials for dementia. A copy of the Implementation Plan is attached.
We are reviewing ways to increase research for dementia and we will set out these ambitions in the forthcoming dementia strategy, which will be published later this year.
To ask Her Majesty's Government what measures the dementia strategy will include to improve patient access to (1) FDG-PET scans, and (2) CSF tests, for an early and accurate diagnosis of Alzheimer’s disease.
To ask Her Majesty's Government what measures the dementia strategy will include to improve patient access to (1) FDG-PET scans, and (2) CSF tests, for an early and accurate diagnosis of Alzheimer’s disease.
We will set out plans for dementia in England, which will include a focus on dementia diagnosis, later this year.
The National Institute for Health and Care Excellence’s (NICE) guidelines provide evidence-based recommendations for health and care, including on assessment, management and support for people living with dementia and their carers. NICE’s guideline Dementia: assessment, management and support for people living with dementia and their carers states that clinicians should consider FDG-PET and CSF tests when the diagnosis of Alzheimer’s disease is uncertain. A copy of the guideline is attached.
Clinical commissioning groups (CCGs) commission the appropriate resources, including such testing, in line with local population health needs. To address dementia waiting lists and increase the number of diagnoses, NHS England and NHS Improvement was allocated £17 million through the Comprehensive Spending Review settlement for mental health in 2021/22. This funding was made available to CCGs in June 2021.
To ask Her Majesty's Government what key performance indicators will be used to assess the success of the dementia strategy.
To ask Her Majesty's Government what key performance indicators will be used to assess the success of the dementia strategy.
We will set out our plans for dementia in England later this year. The strategy will focus on the specific health and care needs of people living with dementia and their carers, including dementia diagnosis, risk reduction and prevention and research. We will work with delivery partners to identify appropriate key performance indicators to monitor progress and assess the success of the strategy.
To ask Her Majesty's Government whether the dementia Moonshot commitment will be delivered as part of the dementia strategy.
To ask Her Majesty's Government whether the dementia Moonshot commitment will be delivered as part of the dementia strategy.
We will set out our plans for dementia in England later this year. The strategy will outline ambitions to increase dementia research and the delivery of the moonshot.